A Decrease font size. A Reset font size. A Increase font size.

Get Your Savings Card

Prescribing Information

Healthcare Professionals

Get Your Savings Card   Healthcare Professionals   Prescribing Information

What is Anemia?
What is the Ferralet® 90 Difference?
Learn More About Iron
Ferralet® 90 Savings
Anemia
Ferralet® 90
Iron

Your patients will

Feel

the Ferralet® 90 difference

Formulated with your patients’ comfort in mind.

Download Important Announcement PDF

Formulated with your patients’ comfort in mind.

Ferralet® 90 Savings

You may be eligible to save money on your prescription by using the Ferralet® 90 Savings Card.*

GET YOUR SAVINGS CARD

To redeem your savings card:

  • Present your prescription, along with the savings card, at your participating pharmacy.
  • Follow your doctor’s instructions on how to take Ferralet 90 and enjoy the nutritional goodness!

*Subject to eligibility. Terms and conditions apply.

Ferralet® 90 Savings

You may be eligible to save money on your Ferralet® 90 prescription by using a Ferralet® 90 Savings Card.*

GET YOUR SAVINGS CARD

To redeem your savings card:

  • Present your prescription, along with the savings card, at your participating pharmacy.
  • Follow your doctor’s instructions on how to take Ferralet 90 and enjoy the nutritional goodness!

* Subject to eligibility. Terms and Conditions apply.

Is Ferralet® 90 indicated for all anemias?

Ferralet® 90 is indicated for the treatment of all anemias that are responsive to oral iron therapy (for instance: hypochromic anemia associated with pregnancy, chronic and/or acute blood loss, metabolic disease, postsurgical convalescence, and dietary needs).1

Ferralet® 90 should be taken as a once-daily tablet, two hours after a meal. As such, some patients prefer bedtime dosing. Tablets should not be chewed.1

Two complimentary iron sources

Printer-Friendly Version

Does Ferralet® 90 offer fewer gastrointestinal (GI) side effects?

GI side effects are a common problem associated with oral iron therapy.2

Ferralet® 90 with Ferr-Ease® was formulated to make iron therapy as gentle and comfortable as possible for your patients.2

Dual-iron for complementary absorption

Ferr-Ease® dual-iron formulation contains both ferrous gluconate and carbonyl iron1:

  • Ferrous gluconate (Fe2+) enters the body in the ferrous state, ready for quick and optimal dissolution and absorption to start restoring your patients’ vital iron levels.3
  • Particulate carbonyl iron (Fe0) requires conversion from its elemental form to the soluble ionized form (Fe0+ 2H+Cl–→Fe2+Cl2 + H2). It is naturally regulated by the patients’ production of gastric acid for gradual absorption.4 Overall, the bioavailability of carbonyl iron is similar to ferrous salts but carbonyl iron has less GI side effects.4

30-70% of patients on oral iron supplements report GI side effects, which may lead to poor adherence to treatment.2

DID YOU KNOW?

Did you know that Ferralet® 90 contains a gentle and effective stool softener (50 mg docusate sodium) that helps prevent constipation that might occur in patients sensitive to iron therapy.5

What is the Ferralet® 90 wholesale information?

Below is the information for Ferralet® 90:

  • NDC 0178-0089-90
  • Packaged in bottles of 90
  • Film-coated tablets
Wholesaler Order Entry Numbers
AmerisourceBergen 10008969
Cardinal Health, Inc 4278834
McKesson Corp 1600634
Morris & Dickson Co. 028886
NC Mutual Wholesale Drug 777276
Smith Drug 634196
Valley Wholesales 378927
Value Drug Co. 497040

References:

1. Ferralet 90 Prescribing Information. San Antonio, TX: Mission Pharmacal Company.
2. Muñoz M, Gómez-Ramírez S, Bhandari S. The safety of available treatment options for iron-deficiency anemia. Expert Opin Drug Saf. 2018;17(2):149-159.
3. Beck KL, Conlon CA, Kruger R, et al. Dietary determinants of and possible solutions to iron deficiency for young women living in industrialized countries: a review. Nutrients. 2014;6(9):3747-3776.
4. Huebers HA, Brittenham GM, Csiba E, et al. Absorption of carbonyl iron. J Lab Clin Med. 1986;108(5):473-478.
5. Medscape. Docusate (OTC). http://reference.medscape.com/drug/colace-dss-docusate-342012. Accessed November 2020.

Mission Pharmacal Company
P.O. Box 786099
San Antonio, TX 78230-1355
210-696-8400

Copyright © 2020 Mission Pharmacal Company. All rights reserved.

Important Safety Information:
Expand COLLAPSE

INDICATIONS: Ferralet® 90 (iron [carbonyl iron, ferrous gluconate] 90 mg, folic acid 1 mg, vitamin B12 [cyanocobalamin] 12 mcg, vitamin C [ascorbic acid] 120 mg, docusate sodium 50 mg) is indicated for the treatment of all anemias responsive to oral iron therapy, such as hypochromic anemia associated with pregnancy, chronic or acute blood loss, dietary needs, metabolic disease and post-surgical convalescence.

Important Safety Information

CONTRAINDICATIONS: Ferralet® 90 is contraindicated in patients:

  • With known hypersensitivity to any of the ingredients
  • With hemolytic anemia, hemochromatosis, or hemosiderosis

WARNINGS: Folic acid alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemias where vitamin B12 is deficient.

WARNING: Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6. KEEP THIS PRODUCT OUT OF THE REACH OF CHILDREN. In case of accidental overdose, call a doctor or poison control center immediately.

PRECAUTIONS:

General: Take 2 hours after meals. Do not exceed recommended dose.  Discontinue use if symptoms of intolerance appear. Before starting Ferralet® 90, determine type and underlying cause(s) of anemia and obtain hemoglobin, hematocrit, and reticulocyte counts.  Repeat laboratory testing periodically during prolonged treatment to determine whether therapy needs to be continued without change or if a dose change is indicated.

This product contains FD&C Yellow No. 5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons. Although the overall incidence of FD&C Yellow No. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who have aspirin hypersensitivity.

Folic Acid: Folic acid in doses above 0.1 mg daily may obscure pernicious anemia in that hematologic remission can occur while neurological manifestations remain progressive. Pernicious anemia should be excluded before using this product since folic acid may mask the symptoms of pernicious anemia.

Pediatric Use: Safety and effectiveness in pediatric patients have not been established.

Geriatric Use: Clinical studies on this product have not been performed in sufficient numbers of subjects aged 65 and over to determine whether elderly subjects respond differently from younger subjects. Dose selection for an elderly patient should be administered with caution, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

ADVERSE REACTIONS: Adverse reactions with iron therapy may include GI irritation, constipation, diarrhea, nausea, vomiting, and dark stools. Adverse reactions with iron therapy are usually transient.  Allergic sensitization has been reported following both oral and parenteral administration of folic acid.

DRUG INTERACTIONS: Prescriber should be aware of a number of iron/drug interactions, including antacids, tetracyclines, or fluoroquinolones.

Please click here for full Prescribing Information.